Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Longitudinal Changes in Body Composition, Adaptive Thermogenesis and Muscle Strength in Patients with Obesity Treated with Semaglutide
Obesity facts, 2026;:1-23
Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with End-Stage Kidney Disease
Clinical journal of the American Society of Nephrology : CJASN, 2026
Clinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database network
Pulmonology, 2026;32(1):2722795
A microencapsulation strategy for intranasal semaglutide delivery
Journal of microencapsulation, 2026;:1-11
Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation
Diabetes, obesity & metabolism, 2026
Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society
Maturitas, 2026;213:109101
Tirzepatide and the risk of asthma exacerbations in patients with type 2 diabetes
Frontiers in endocrinology, 2026;17:1928877
Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management
Current pain and headache reports, 2026;30(1)
Exploring The Role of GLP-1 Receptor Agonists and DPP4 Inhibitors in the Treatment of Opioid Use Disorder: A Scoping Review
Journal of dual diagnosis, 2026;:1-14
GLP-1 receptor agonists and outcomes after cervical spine fusion: a systematic review, meta-analysis, and evidence map of real-world evidence
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2026
Synthetic Versus Reference Semaglutide for Weight Management: Reporting Gaps and Clinical Claims
Diabetes, obesity & metabolism, 2026
Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis
Diabetes, obesity & metabolism, 2026
Highlights from JAAD Reviews: Skin in the Game: Dermatologic and Medicolegal Aspects of GLP-1 Receptor Agonists
Journal of the American Academy of Dermatology, 2026
Dual-transporter-targeted oral nanomicelles of semaglutide enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes
Journal of controlled release : official journal of the Controlled Release Society, 2026;:115297
Pathogenesis-Informed Phenotype-Guided Therapy for MASH: A Three-Axis Translational Framework Within the MASLD Spectrum
Biomedicines, 2026;14(9)
Responders Vs. Non-Responders or How to Predict the Response to GLP-1 or GLP-1/GIP Receptor Agonist Therapy
Diabetes, obesity & metabolism, 2026
Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs)
Naunyn-Schmiedeberg's archives of pharmacology, 2026
Lifestyle Medicine as Co-Therapy During Incretin-Based Anti-Obesity Pharmacotherapy: Integrating Physical Activity, Nutrition, and Behavioral Strategies for Long-Term Success
Nutrients, 2026;18(17)
Long-Term Clinical Outcomes and Real-World Effectiveness of Tirzepatide in Adults With Overweight or Obesity: A Systematic Review
Cureus, 2026;18(8):e114962
Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes
Nature communications, 2026;17(1)